@Fastback6666 I'm not sure that is the case .... well it is not what it says in the original GVHD trial notification and / or today's HY Report (see below extract) ?
It is my understanding that the costs will be shared by BMT CTN and Mesoblast, but I don't recall seeing confirmation that BMT CTN are contributing 80% of the total costs ? If the 80% figure you are quoting is from the ASX announcements below, then I am not sure you are reading it right because that isn't what it says ? It says BMT CTN centers are responsible for approximately 80% of all US allogeneic bone marrow transplants (BMTs) not 80% of the upcoming Mesoblast sr-GVHD trial costs ?
" Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, "
Happy for you to show me where you got this 80% figure from if it is from somewhere else and it is the case that BMT CTN are paying this large percentage of costs ?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)